文献速递淋巴瘤

微小残留病对套细胞淋巴瘤利妥昔单抗维持治疗疗效的预测价值:欧洲套细胞淋巴瘤老年试验结果

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
PubMed 文献 · J Clin Oncol · 2023-11-22

欧洲套细胞淋巴瘤老年试验中,288例患者80%可生成中位灵敏度1×10-5的qPCR检测。诱导结束时MRD阴性者接受利妥昔单抗维持治疗可显著改善PFS(HR 0.38)和OS(HR 0.37),MRD阳性者疗效较差。诱导后临床缓解但MRD阳性者中位至临床进展时间约1-1.7年。

要点

  • 诱导结束时MRD阴性者接受利妥昔单抗维持治疗,PFS HR 0.38、OS HR 0.37。
  • R-CHOP诱导后MRD阴性者获益更明显,PFS HR 0.23、OS HR 0.19。
  • MRD阳性者利妥昔单抗维持治疗PFS HR 0.51,95%CI跨1。

核心结论

  • 结果证实利妥昔单抗维持治疗对诱导后MRD阴性患者具有强效作用。
  • 作者认为其结果不支持对MRD阴性患者进行治疗降阶梯。
  • 作者建议在MRD阳性患者中探索更有效的巩固策略以改善长期预后。

研究设计与样本

  • 欧洲套细胞淋巴瘤老年试验的前瞻性计划部分,纳入初治60岁及以上套细胞淋巴瘤患者。
  • 患者随机接受利妥昔单抗或干扰素-α维持治疗,诱导方案为R-FC或R-CHOP。
  • MRD监测按EuroMRD指南采用实时定量聚合酶链反应(qPCR)进行。

主要发现

  • 288例患者中80%可生成qPCR检测,中位灵敏度为1×10-5。
  • 诱导结束时MRD阴性者中,利妥昔单抗维持治疗对比干扰素-α维持治疗的PFS HR为0.38(95%CI 0.21-0.63),OS HR为0.37(95%CI 0.20-0.68)。
  • R-CHOP治疗患者中,MRD阴性者利妥昔单抗维持治疗的PFS HR为0.23(95%CI 0.10-0.52),OS HR为0.19(95%CI 0.07-0.52)。
  • MRD阳性者中,利妥昔单抗维持治疗总体PFS HR为0.51(95%CI 0.26-1.02),R-CHOP诱导后PFS HR为0.59(95%CI 0.28-1.26)。
  • R-FC较R-CHOP实现更频繁且更快的MRD清除;诱导后临床缓解但MRD阳性者中位至临床进展时间约1-1.7年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The outcome of older patients with mantle cell lymphoma (MCL) has improved by the introduction of immunochemotherapy, followed by rituximab (R)-maintenance. Assessment of minimal residual disease (MRD) represents a promising tool for individualized treatment decisions and was a prospectively planned part of the European MCL Elderly trial. We investigated how MRD status influenced the efficacy of R-maintenance and how MRD can enable tailored consolidation strategies. PATIENTS AND METHODS: Previously untreated patients with MCL age 60 years or older have been randomly assigned to R versus interferon-alpha maintenance after response to rituximab, fludarabine, cyclophosphamide (R-FC) versus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). MRD monitoring was performed by real-time quantitative polymerase chain reaction (qPCR) following EuroMRD guidelines. RESULTS: A qPCR assay with a median sensitivity of 1 × 10-5 could be generated in 80% of 288 patients in an international, multicenter, multilaboratory setting. More extensive tumor dissemination facilitated the identification of a molecular marker. The efficacy of R-maintenance in clinical remission was confirmed for MRD-negative patients at the end of induction in terms of progression-free survival (PFS; hazard ratio [HR], 0.38 [95% CI, 0.21 to 0.63]) and overall survival (OS; HR, 0.37 [95% CI, 0.20 to 0.68]), particularly in R-CHOP-treated patients (PFS-HR, 0.23 [95% CI, 0.10 to 0.52]; OS-HR, 0.19 [95% CI, 0.07 to 0.52]). R-maintenance appeared less effective in MRD-positive patients (PFS-HR, 0.51 [95% CI, 0.26 to 1.02]) overall and after R-CHOP induction (PFS-HR, 0.59 [95% CI, 0.28 to 1.26]). R-FC achieved more frequent and faster MRD clearance compared with R-CHOP. MRD positivity in clinical remission after induction was associated with a short median time to clinical progression of approximately 1-1.7 years. CONCLUSION: The results confirm the strong efficacy of R-maintenance in patients who are MRD-negative after induction. Treatment de-escalation for MRD-negative patients is discouraged by our results. More effective consolidation strategies should be explored in MRD-positive patients to improve their long-term prognosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hoster E, Delfau-Larue MH, Macintyre E, et al. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial. J Clin Oncol. 2023. PMID: 37992261. doi:10.1200/JCO.23.00899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。